摘要: Colorectal cancer remains the second leading cause of cancer-related death in United States. While chemo- therapy backbone upon which treatment for meta- static colorectal is built, targeted therapies have been employed, albeit with mixed results, management this disease. Nonetheless, increased understanding recent years complexity and heterogeneity cellular abnormalities driving these tumors has identified potential targets future interven- tions. This article will review seminal biomarkers predic- tive prognostic importance currently used patients cancer, highlight additional promising may be incorporated into clinical practice future.
参考文章(120)
Stephen N. Thibodeau, Lawrence J. Burgart, David J. Tester, Eric R. Christensen, Patrick C. Roche, Julie M. Cunningham, Cheong Yong Kim, Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability Cancer Research. ,vol. 58, pp. 3455- 3460 ,(1998)
Jolien Tol, Miriam Koopman, Annemieke Cats, Cees J. Rodenburg, Geert J.M. Creemers, Jolanda G. Schrama, Frans L.G. Erdkamp, Allert H. Vos, Cees J. van Groeningen, Harm A.M. Sinnige, Dirk J. Richel, Emile E. Voest, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Ninja F. Antonini, Linda Mol, Johan H.J.M. van Krieken, Otilia Dalesio, Cornelis J.A. Punt, Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 360, pp. 563- 572 ,(2009) , 10.1056/NEJMOA0808268
Christine M. Ribic, Daniel J. Sargent, Malcolm J. Moore, Stephen N. Thibodeau, Amy J. French, Richard M. Goldberg, Stanley R. Hamilton, Pierre Laurent-Puig, Robert Gryfe, Lois E. Shepherd, Dongsheng Tu, Mark Redston, Steven Gallinger, Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer The New England Journal of Medicine. ,vol. 349, pp. 247- 257 ,(2003) , 10.1056/NEJMOA022289
J. Randolph Hecht, Edith Mitchell, Marcus A. Neubauer, Howard A. Burris, Paul Swanson, Timothy Lopez, Glenn Buchanan, Maureen Reiner, Jennifer Gansert, Jordan Berlin, Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer Clinical Cancer Research. ,vol. 16, pp. 2205- 2213 ,(2010) , 10.1158/1078-0432.CCR-09-2017
Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Celeste Lebbe, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven J. O'Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur, Paul B. Chapman, Axel Hauschild, Caroline Robert, John B. Haanen, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation The New England Journal of Medicine. ,vol. 364, pp. 2507- 2516 ,(2011) , 10.1056/NEJMOA1103782
Yardena Samuels, Zhenghe Wang, Alberto Bardelli, Natalie Silliman, Janine Ptak, Steve Szabo, Hai Yan, Adi Gazdar, Steven M Powell, Gregory J Riggins, James KV Willson, Sanford Markowitz, Kenneth W Kinzler, Bert Vogelstein, Victor E Velculescu, High Frequency of Mutations of the PIK3CA Gene in Human Cancers Science. ,vol. 304, pp. 554- 554 ,(2004) , 10.1126/SCIENCE.1096502
M R Bordoli, D P Stiehl, L Borsig, G Kristiansen, S Hausladen, P Schraml, R H Wenger, G Camenisch, Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis Oncogene. ,vol. 30, pp. 548- 560 ,(2011) , 10.1038/ONC.2010.433
PL Barratt, MT Seymour, SP Stenning, I Georgiades, C Walker, K Birbeck, P Quirke, None, DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study The Lancet. ,vol. 360, pp. 1381- 1391 ,(2002) , 10.1016/S0140-6736(02)11402-4
Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, Igor Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, Fortunato Ciardiello, Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Journal of Clinical Oncology. ,vol. 29, pp. 2011- 2019 ,(2011) , 10.1200/JCO.2010.33.5091
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent-Puig, Frédérique Penault-Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric Di Fiore, Alice Oden Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar, None, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncology. ,vol. 11, pp. 753- 762 ,(2010) , 10.1016/S1470-2045(10)70130-3